Prostate Cancer
Clinical research is centred on metastatic castration-resistant prostate cancer, with a focus on disease control in men whose cancer has progressed despite standard hormonal suppression.
- Metastatic castration-resistant prostate cancer
- Anti-androgen–naïve population
- Advanced prostate malignancy
The sponsor’s activity in this area reflects interest in treatment-resistant prostate disease and the search for more effective oncology options.
Androgen Receptor Pathway Targeting
Research includes therapies directed at the androgen receptor axis, a central driver of prostate cancer growth and progression.
- Androgen receptor inhibition
- Hormone-resistant disease
- Second-generation anti-androgen therapy
This therapeutic area is relevant to patients whose tumours remain dependent on androgen signalling despite prior hormonal treatment.
Combination Cancer Therapy
Clinical interest extends to combining agents with established prostate cancer treatments to assess whether dual targeting can improve tumour control.
- Combination therapy
- Antitumour activity
- Therapeutic synergy
The sponsor is involved in evaluating how investigational small-molecule approaches may complement existing hormonal agents in advanced disease.
Oncology Safety and Tolerability
A key research focus is the assessment of safety and tolerability in patients receiving treatment for advanced cancer.
- Adverse effects
- Dose-limiting toxicities
- Maximum tolerated dose
These interests support the development of regimens suitable for long-term management of metastatic disease.
